The Relationship of Platelet Counts With Sickle Cell Anemia in the Eastern Region of Saudi Arabia

October 3, 2024 updated by: Khalid Ali Majrashi, Majmaah University
This study aims to evaluate the relationship between platelet counts and sickle cell disease in the eastern region of the Kingdom of Saudi Arabia.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Introduction:

This study aims to evaluate the relationship between platelet counts and sickle cell disease in the eastern region of the Kingdom of Saudi Arabia.

Purpose: This study aims to assess the prevalence and factors associated with elevated platelet counts in people with sickle cell disease in the eastern region of Saudi Arabia.

Methods: This cross-sectional study at Majmaah University will analyze prerecorded data frfom the eastern region of Saudi Arabia to investigate the relationship between platelet counts and sickle cell disease, identifying associated factors and assessing the link .

Importance: To assess the relationship between platelet counts and disease severity in Pationt with SCD.

Aim :To investigate the relationship between platelet counts and SCD in the eastern region of the Kingdom of Saudi Arabia.

Study Type

Observational

Enrollment (Estimated)

650

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Saudi Arabia
      • Dammam, Saudi Arabia
        • Khalid Ali Majrashi
        • Contact:
        • Principal Investigator:
          • KHALID A MAJRASHI

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

The study will include a cohort of people with SCD who are registered at the Hereditary Blood center al-ahssa.

Description

Inclusion criteria: All the diagnosed patients of sickle cell disease regardless of age and gender.

Exclusion criteria: Patients without having sickle cell disease regardless of age and gender.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Males
The study will be conducted on CBC count special PLT for adult Males of different ages with sickle cell anemia.
Diagnostic test: Platelets count
the study include will take medical investigation data for all sickle cell patients.
Children
The study will be conducted on CBC count special PLT for adult Males of different ages with sickle cell anemia.
Diagnostic test: Platelets count
the study include will take medical investigation data for all sickle cell patients.
Females
The study will be conducted on CBC count special PLT for adult Males of different ages with sickle cell anemia.
Diagnostic test: Platelets count
the study include will take medical investigation data for all sickle cell patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Collecting platelet data for sickle cell anemia patients
Time Frame: From January 2023 to December 2023
Collecting platelet data for sickle cell anemia patients in males and female and children based on different ages, then analyzing them and studying their relationship
From January 2023 to December 2023

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Majmaah University

Investigators

  • Principal Investigator: Khalid A Majrashi, Majmaah University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2024

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

March 30, 2025

Study Registration Dates

First Submitted

September 16, 2024

First Submitted That Met QC Criteria

September 17, 2024

First Posted (Actual)

September 19, 2024

Study Record Updates

Last Update Posted (Actual)

October 4, 2024

Last Update Submitted That Met QC Criteria

October 3, 2024

Last Verified

October 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB Log No.: 29-EP-2024

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on SCD

Clinical Trials on Platelets count

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe